CD30 CAR T has also been evaluated in combination with a PD1 inhibitor in a Phase 2 trial conducted in 12 CD30 positive lymphoma patients (9 HL, 2 grey zone and 1 angioimmunoblastic lymphoma) with some durable responses [84]. The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.